Introduction:
Cardiac and cerebrovascular events are the leading cause of death in patients with end-stage renal disease (ESRD) undergoing hemodialysis, more than 50% of all deaths with known causes. Hypervolemia is one of the strongest risk factors for mortality in these patients. Profibrotic changes in the heart and the vascular bed due to hypervolemia is considered to be one of the main triggering factors in the pathway leading to LV hypertrophy and dysfunction in dialysis. Cardiac preload and LV dilatation are main adaptive response to increase the heart muscle's pumping ability.
Methods:
Dialysis patients who had been receiving treatment at the same facility for at least three months were included in the study. Patients were given treatment twice weekly, with hydration status checked just before each central HD using a variety of methods. Echocardiography using a Phillips Envisor -C model (serial number 60506535) to get images in the "parasternal long-axis view". We have used the portable USG probe software to measure the left ventricular end-diastolic dimensions, the thickness of the interventricular septum, and the thickness of the posterior wall. The information was used to calculate the volume of muscle in the left ventricle, as recommended by the ASE. The (LVMi) was computed by adjusting the patient's left ventricular muscle mass score for the patient's height and weight.
Results:
Results shows that the average left ventricular mass decreased from 244.13 grams in the first month to 236.97 grams in the third month and the average LVMi to body surface area also decreased slightly from 134.99 grams per square meter to 133.05 grams per square meter over the same period. These findings suggest a modest decline in heart-related measurements between the first and third months of observation after adjusting dry weight. There is still a highly significant difference (mean difference 7.16262, p = 0.000) between the first and third months in LV Mass, even at the stricter 0.01 level. The difference remains not significant (mean difference 1.93836, p = 0.484) at the 0.01 level, confirming that the disparity in LVM Index values between the first and third months is not statistically meaningful.
Conclusions:
In conclusion, Haemodialysis patients need dry weight measurement to maintain fluid balance, optimise cardiovascular health, reduce symptoms, and personalise medication. It prevents fluid excess and dehydration, enhancing patients' quality of life. Maintaining an appropriate dry weight and meeting patient demands requires regular monitoring and modifications.
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.